GOLD 2026 Guidelines in the Comprehensive Management of Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD) is a leading cause of chronic morbidity and mortality worldwide. It is a progressive inflammatory airway disease that develops through complex, prolonged interactions between genetic factors and environmental exposures over an individual’s lifetime—a concept referred to as GETomics (Gene–Environment–Time interactions).^[1] These interactions drive chronic airway inflammation, structural lung damage, and irreversible airflow obstruction. As the disease advances, recurrent exacerbations, declining lung function, systemic inflammation, and extrapulmonary manifestations collectively worsen functional status, reduce quality of life, and increase mortality, ultimately shaping the long-term clinical outcomes of COPD.^[2] 

To address these challenges, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) provides regularly updated, evidence-based recommendations to optimize the diagnosis, management, and prevention of COPD. The GOLD 2026 report includes refinements in clinical classification, management strategies, exacerbation care, comorbidity assessment, and emerging therapeutic approaches. 

Patients with COPD commonly present with multiple symptoms, including dyspnea on exertion, chronic cough, sputum production, and recurrent respiratory infections, which may worsen during acute exacerbations.^[3] However, diagnosis requires confirmation of persistent airflow limitation using spirometry, defined as a post-bronchodilator FEV₁/FVC ratio < 0.70 in the appropriate clinical context.^[1] 

Symptoms are assessed using validated tools such as the modified Medical Research Council (mMRC) dyspnea scale and the COPD Assessment Test (CAT). Exacerbation history, including frequency and severity, is a key determinant of disease classification and therapeutic decisions. Even a single moderate exacerbation before initiating therapy increases future risk and influences treatment selection.^[1]

The primary goals of COPD management are to:

• Relieve respiratory symptoms and improve quality of life

• Enhance exercise tolerance and functional capacity

• Reduce the frequency and severity of exacerbations

• Prevent disease progression and minimize future risk

• Improve survival through risk reduction and evidence-based therapy ^[1]
   

Effective COPD management requires an integrated approach combining pharmacological and non-pharmacological interventions.^[1],[4]

single moderate exacerbation system based on symptom burden and exacerbation risk:

• Group A: Low symptoms, low exacerbation risk

• Group B: High symptoms, low exacerbation risk

• Group E: High exacerbation risk, regardless of symptom burden

This framework emphasizes exacerbation risk as a key driver of treatment decisions.^[1]

2.1 Monotherapy

For Group A patients, initial therapy includes either a long-acting muscarinic antagonist (LAMA) or a long-acting β₂-agonist (LABA).^[1]

2.2 Dual Bronchodilation

For Group B patients with persistent symptoms, dual bronchodilation with LABA/LAMA is recommended. Evidence shows that LABAs and LAMAs both improve lung function, reduce dyspnea, enhance quality of life, and reduce exacerbation rates. LAMAs may be superior to LABAs in reducing exacerbations, particularly in moderate-to-very severe disease, with long-term safety confirmed in the UPLIFT trial. LABA/LAMA combinations (e.g., umeclidinium/vilanterol, glycopyrronium/formoterol, tiotropium/olodaterol, aclidinium/formoterol) provide additive benefits without increasing adverse effects, improving FEV₁, health-related quality of life, and reducing exacerbation rates.^[4]

ICS therapy is not recommended for routine use in all COPD patients. It is reserved for patients with frequent or severe exacerbations despite optimized bronchodilator therapy, particularly those with elevated blood eosinophils (≥300 cells/μL), to maximize benefit while minimizing risks such as pneumonia.^[1],[5]

Treatment should be individualized and regularly reassessed based on symptom control, exacerbation frequency, inhaler technique, and blood eosinophil counts. GOLD 2026 distinguishes between initial treatment and follow-up optimization, with clear algorithms guiding therapy escalation or de-escalation.^[1] 

Figure 1: Initial pharmacological treatment algorithm for COPD according to GOLD Initiative for COPD 2026. Adapted from the GOLD 2026 Pocket Guide.^[1] 

Exacerbations are acute deteriorations that significantly increase morbidity, hospitalization, and mortality. Management requires a structured approach:

The management of acute COPD exacerbations requires prompt intervention to prevent clinical deterioration, hospitalization, and mortality. Initial therapy involves intensifying short-acting bronchodilators to rapidly relieve airflow limitation and improve symptom control. A short course of systemic corticosteroids, typically lasting five days or less, is recommended to reduce airway inflammation and shorten recovery time. Antibiotics should be administered when a bacterial infection is suspected, based on clinical presentation and sputum characteristics. In patients with acute hypercapnic respiratory failure, non-invasive ventilation is indicated to improve gas exchange and reduce the need for invasive mechanical ventilation. Oxygen therapy should be carefully titrated to maintain target saturations between 88% and 92%, minimizing the risk of oxygen-induced hypercapnia while ensuring adequate tissue oxygenation.^[1]

Following stabilization from an acute exacerbation, maintenance therapy should be carefully individualized and adjusted according to the patient’s symptom burden, history of exacerbations, and adherence to inhaler therapy. For patients who continue to experience persistent dyspnea despite dual bronchodilation with a LABA–LAMA combination, clinicians should consider switching inhaler devices or molecules to optimize drug delivery and response. Additionally, non-pharmacological interventions, such as pulmonary rehabilitation, should be intensified, and alternative causes of dyspnea—including cardiac disease, pulmonary embolism, or physical deconditioning—should be systematically investigated. In selected patients, novel therapies such as ensifentrine may be introduced to further alleviate symptoms.^[5]

For individuals who continue to experience frequent or severe exacerbations despite optimized bronchodilator therapy, escalation of treatment may be warranted. This can include the addition of inhaled corticosteroids (ICS) in combination with a LABA or, in certain cases, triple therapy with ICS–LABA–LAMA, particularly in patients with elevated blood eosinophil counts.^[5] Further escalation options may involve the use of roflumilast, long-term azithromycin (preferentially in former smokers), or targeted biologic therapies such as dupilumab and mepolizumab, applied selectively to carefully chosen phenotypes to maximize benefit and minimize risk.^[1] 

Figure 2: Follow up Pharmacological Treatment according to the GOLD Initiative for COPD 2026. Adapted from the GOLD 2026 Pocket Guide.^[1] 

Non-pharmacological interventions are essential to complement pharmacological therapy, improve symptoms, reduce exacerbations, and enhance long-term outcomes.^[3]

• Smoking cessation: behavioral counseling, nicotine replacement, and pharmacologic support (varenicline, bupropion)

• Pulmonary rehabilitation: structured exercise, education, behavioral interventions improve dyspnea, exercise tolerance, and quality of life

• Vaccinations: influenza, pneumococcal, COVID-19, and others reduce infection risk and subsequent exacerbations

• Long-term oxygen therapy: indicated in chronic hypoxemia to improve survival

• Exercise & lifestyle modifications: prevent deconditioning and maintain functional capacity

• Nutritional support: address malnutrition or obesity to optimize respiratory function

• Patient education & self-management: inhaler training, individualized action plans, early intervention for exacerbations, adherence promotion.^[1] 

By combining these strategies with optimized pharmacological therapy, clinicians can effectively reduce symptom burden, prevent exacerbations, and improve long-term outcomes.^[4]

COPD frequently coexists with cardiovascular disease, metabolic disorders, sleep-related breathing disorders, and mental health conditions.^[6] GOLD 2026 emphasizes integrated management of comorbidities to improve overall health outcomes and quality of life.^[1] 

The GOLD 2026 guidelines provide a comprehensive, patient-centered framework for COPD management. By integrating symptom assessment, exacerbation risk evaluation, pharmacological and non-pharmacological strategies, and individualized follow-up, these guidelines support evidence-based clinical decision-making and improved patient outcomes. 

SERETIDE is contraindicated in patients with a history of hypersensitivity to any of the ingredients. 

Very common adverse events (≥1/10): Headache. 

Common adverse events (≥1/100 to <1/10) include candidiasis of the mouth and throat, pneumonia (in COPD patients), hoarseness/dysphonia, muscle cramps, and arthralgia.

Before prescribing, please refer to the full prescribing information.

Seretide Accuhaler

Seretide Evohaler

A WORD FROM DOC2US DOC2US is a mobile application that allows patients to talk to a physician or any healthcare professional via text chat at any time and from anywhere. For better communication, they can even send our online physician images or voice messages related to their medical inquiry. To join our platform as a healthcare provider please visit our page here. 

Disclaimer: This article exclusively provides medical updates for Healthcare Professionals, serving as a guideline to enhance practices without promoting specific drugs. It advises on responsible medication dispensation, emphasising patient safety and discouraging illegal transactions. You are welcome to use the DOC2US Electronic Prescribing System and be a part of our authorised partner pharmacists. Sign up today here!

PM-MY-UCV-WCNT-250002 02/26

For Malaysia Healthcare Professionals Only
GlaxoSmithKline Pharmaceutical Sdn Bhd
195801000141(3277-U)
HZ.01, Horizon Penthouse, 1 Powerhouse, 1,
Persiaran Bandar Utama, Bandar Utama,
47800 Petaling Jaya, Selangor Darul Ehsan, Malaysia
Tel: (603) 2037 9808
www.my.gsk.com
 
Trademarks are owned by licensed to the GSK group of the companies

©2026 GSK group of companies or its licensor.
Adverse events should be reported to: drugsafetyinfo.my@gsk.com
This educational program is sponsored by GSK

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: 2026 report [Internet]. 2026 [cited 2026 Feb 12]. Available from: https://goldcopd.org

2. Jo YS. Long-term outcome of chronic obstructive pulmonary disease: a review. Tuberc Respir Dis (Seoul). 2022;85(4):289–301. doi:10.4046/trd.2022.0074.

3. Celli BR, Fabbri LM, Aaron SD, Agusti A, Brook RD, Criner GJ, et al. Differential diagnosis of suspected chronic obstructive pulmonary disease exacerbations in the acute care setting: best practice. Am J Respir Crit Care Med. 2023;207(9):1134–44. doi:10.1164/rccm.202209-1795CI.

4. BMJ Best Practice. Chronic obstructive pulmonary disease (COPD) – management approach [Internet]. London: BMJ Publishing Group; 2024 [cited 2026 Feb 12. Available from: https://bestpractice.bmj.com/topics/en-gb/7/management-approach

5. Khan KS, Jawaid S, Memon UA, Perera T, Khan U, Farwa UE, et al. Management of chronic obstructive pulmonary disease (COPD) exacerbations in hospitalized patients from admission to discharge: a comprehensive review of therapeutic interventions. Cureus. 2023;15(8):e43694. doi:10.7759/cureus.43694.

6. Almagro P, Soler-Cataluña JJ, Huerta A, González-Segura D, Cosío BG; CLAVE Study Investigators. Impact of comorbidities in COPD clinical control criteria. BMC Pulm Med. 2024;24(1):6. doi:10.1186/s12890-023-02758-0.

Written By

Rosamund Koo

Pharmacist

Reviewed By

Dr Jessica Kaur

Doctor